Asunto(s)
Biomarcadores de Tumor/genética , Trastornos de las Plaquetas Sanguíneas/complicaciones , Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Leucemia Mieloide Aguda/etiología , Mutación/genética , Leucemia-Linfoma Linfoblástico de Células T Precursoras/etiología , Adolescente , Adulto , Trastornos de las Plaquetas Sanguíneas/genética , Plaquetas/patología , Niño , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Leucemia Mieloide Aguda/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Linaje , Leucemia-Linfoma Linfoblástico de Células T Precursoras/patología , PronósticoRESUMEN
BACKGROUND AND OBJECTIVES: Anagrelide represents a treatment option for essential thrombocythemia patients. It lowers platelet counts through inhibition of megakaryocyte maturation and polyploidization, although the basis for this effect remains unclear. Based on its rapid onset of action, we assessed whether, besides blocking megakaryopoiesis, anagrelide represses proplatelet formation (PPF) and aimed to clarify the underlying mechanisms. METHODS AND RESULTS: Exposure of cord blood-derived megakaryocytes to anagrelide during late stages of culture led to a dose- and time-dependent inhibition of PPF and reduced proplatelet complexity, which were independent of the anagrelide-induced effect on megakaryocyte maturation. Whereas anagrelide was shown to phosphorylate cAMP-substrate VASP, two pharmacologic inhibitors of the cAMP pathway were completely unable to revert anagrelide-induced repression in megakaryopoiesis and PPF, suggesting these effects are unrelated to its ability to inhibit phosphodiesterase (PDE) 3. The reduction in thrombopoiesis was not the result of down-regulation of transcription factors which coordinate PPF, while the myosin pathway was identified as a candidate target, as anagrelide was shown to phosphorylate the myosin light chain and the PPF phenotype was partially rescued after inhibition of myosin activity with blebbistatin. CONCLUSIONS: The platelet-lowering effect of anagrelide results from impaired megakaryocyte maturation and reduced PPF, both of which are deregulated in essential thrombocythemia. These effects seem unrelated to PDE3 inhibition, which is responsible for anagrelide's cardiovascular side-effects and antiplatelet activity. Further work in this field may lead to the potential development of drugs to treat thrombocytosis in myeloproliferative disorders with an improved pharmacologic profile.
Asunto(s)
Plaquetas/efectos de los fármacos , Células Madre Hematopoyéticas/efectos de los fármacos , Megacariocitos/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Quinazolinas/farmacología , Trombocitemia Esencial/tratamiento farmacológico , Trombopoyesis/efectos de los fármacos , Plaquetas/metabolismo , Estudios de Casos y Controles , Moléculas de Adhesión Celular/metabolismo , Células Cultivadas , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Sangre Fetal/citología , Células Madre Hematopoyéticas/metabolismo , Compuestos Heterocíclicos de 4 o más Anillos/farmacología , Humanos , Megacariocitos/metabolismo , Proteínas de Microfilamentos/metabolismo , Miosinas/metabolismo , Inhibidores de Fosfodiesterasa 3/farmacología , Fosfoproteínas/metabolismo , Fosforilación , Transducción de Señal/efectos de los fármacos , Trombocitemia Esencial/sangre , Trombocitemia Esencial/diagnóstico , Factores de Tiempo , Factores de Transcripción/metabolismoRESUMEN
BACKGROUND: Familial platelet disorder with a predisposition to acute myelogenous leukemia (FPD/AML) is an inherited platelet disorder caused by a germline RUNX1 mutation and characterized by thrombocytopenia, a platelet function defect, and leukemia predisposition. The mechanisms underlying FPD/AML platelet dysfunction remain incompletely clarified. We aimed to determine the contribution of platelet structural abnormalities and defective activation pathways to the platelet phenotype. In addition, by using a candidate gene approach, we sought to identify potential RUNX1-regulated genes involved in these defects. METHODS: Lumiaggregometry, α-granule and dense granule content and release, platelet ultrastructure, αIIb ß3 integrin activation and outside-in signaling were assessed in members of one FPD/AML pedigree. Expression levels of candidate genes were measured and luciferase reporter assays and chromatin immunoprecipitation were performed to study NF-E2 regulation by RUNX1. RESULTS: A severe decrease in platelet aggregation, defective αIIb ß3 integrin activation and combined αδ storage pool deficiency were found. However, whereas the number of dense granules was markedly reduced, α-granule content was heterogeneous. A trend towards decreased platelet spreading was found, and ß3 integrin phosphorylation was impaired, reflecting altered outside-in signaling. A decrease in the level of transcription factor p45 NF-E2 was shown in platelet RNA and lysates, and other deregulated genes included RAB27B and MYL9. RUNX1 was shown to bind to the NF-E2 promoter in primary megakaryocytes, and wild-type RUNX1, but not FPD/AML mutants, was able to activate NF-E2 expression. CONCLUSIONS: The FPD/AML platelet function defect represents a complex trait, and RUNX1 orchestrates platelet function by regulating diverse aspects of this process. This study highlights the RUNX1 target NF-E2 as part of the molecular network by which RUNX1 regulates platelet biogenesis and function.
Asunto(s)
Trastornos de las Plaquetas Sanguíneas/sangre , Trastornos de las Plaquetas Sanguíneas/complicaciones , Plaquetas/citología , Subunidad alfa 2 del Factor de Unión al Sitio Principal/metabolismo , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/complicaciones , Adenosina Trifosfato/metabolismo , Adulto , Salud de la Familia , Femenino , Perfilación de la Expresión Génica , Humanos , Integrina beta3/metabolismo , Masculino , Subunidad p45 del Factor de Transcripción NF-E2/metabolismo , Linaje , Fenotipo , Fosforilación , Agregación Plaquetaria , Pruebas de Función Plaquetaria , Glicoproteína IIb de Membrana Plaquetaria/metabolismo , Transducción de Señal , Tirosina/metabolismo , Adulto JovenRESUMEN
BACKGROUND: Inherited thrombocytopenias (ITs) are heterogeneous genetic disorders that frequently represent a diagnostic challenge. The requirement of highly specialized tests for diagnosis represents a particular problem in resource-limited settings. To overcome this difficulty, we applied a diagnostic algorithm and developed a collaboration program with a specialized international center in order to increase the diagnostic yield in a cohort of patients in Argentina. METHODS: Based on the algorithm, initial evaluation included collection of clinical data, platelet size, blood smear examination and platelet aggregation tests. Confirmatory tests were performed according to diagnostic suspicion, which included platelet glycoprotein expression, immunofluorescence for myosin-9 in granulocytes and platelet thrombospondin-1 and molecular screening of candidate genes. RESULTS: Thirty-one patients from 14 pedigrees were included; their median age was 32 (4-72) years and platelet count 72 (4-147)×10(9) L(-1). Autosomal dominant inheritance was found in nine (64%) pedigrees; 10 (71%) had large platelets and nine (29%) patients presented with syndromic forms. A definitive diagnosis was made in 10 of 14 pedigrees and comprised MYH9-related disease in four, while classic and monoallelic Bernard-Soulier syndrome, gray platelet syndrome, X-linked thrombocytopenia, thrombocytopenia 2 (ANKRD26 mutation) and familial platelet disorder with predisposition to acute myelogenous leukemia were diagnosed in one pedigree each. CONCLUSIONS: Adoption of an established diagnostic algorithm and collaboration with an expert referral center proved useful for diagnosis of IT patients in the setting of a developing country. This initiative may serve as a model to develop international networks with the goal of improving diagnosis and care of patients with these rare diseases.
Asunto(s)
Conducta Cooperativa , Países en Desarrollo , Pruebas Genéticas , Pruebas Hematológicas , Cooperación Internacional , Trombocitopenia/diagnóstico , Adolescente , Adulto , Anciano , Algoritmos , Argentina , Biomarcadores/sangre , Niño , Preescolar , Análisis Mutacional de ADN , Estudios de Factibilidad , Femenino , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Predisposición Genética a la Enfermedad , Pruebas Genéticas/métodos , Accesibilidad a los Servicios de Salud , Pruebas Hematológicas/métodos , Herencia , Humanos , Italia , Masculino , Persona de Mediana Edad , Proteínas Motoras Moleculares/sangre , Cadenas Pesadas de Miosina/sangre , Linaje , Fenotipo , Recuento de Plaquetas , Pruebas de Función Plaquetaria , Valor Predictivo de las Pruebas , Pronóstico , Derivación y Consulta , Trombocitopenia/sangre , Trombocitopenia/congénito , Trombospondina 1/sangre , Adulto JovenRESUMEN
The aim of this study was to evaluate cell maturation and the platelet production capacity of the megakaryoblastic DAMI cell line, to characterize platelet-like particles produced and to investigate the mechanisms involved in their production. DAMI cell maturation was induced by phorbol myristate acetate (PMA) and thrombopoietin (TPO). Expression levels of GATA-1, Fli-1 and NF-E2 were evaluated using real-time PCR and western blot. Platelet-like particles were characterized by the presence of GPIb and GPIIb by flow cytometry, while the soluble fragment of GPIb, glycocalicin, was detected by enzyme immunoassay. Dense and alpha granules were evaluated by mepacrine staining and thrombospondin-1 detection, respectively, and by electron microscopy. Functional capacity of platelet-like particles was studied by measuring P-selectin membrane after thrombin stimulation by flow cytometry and actin polymerization using phalloidin-FITC by immunofluorescence. We found that stimulation of DAMI cells with high concentration of PMA and TPO induced the expression of transcription factors GATA-1 and Fli-1 followed by an increase in the isoform a of NF-E2. Mature DAMI cells give rise to extensions resembling proplatelets and later, produce platelet-like particles expressing GPIIb and GPIb on their surface and containing dense and alpha granules, which were confirmed by electron microscopy. Platelet functionality was demonstrated by the increase in P-selectin membrane expression after thrombin stimulation and by their ability to spread on fibrinogen matrices. DAMI cell line induced to differentiate into mature megakaryocytes is able to produce functional platelets providing a suitable model to study the mechanisms involved in platelet generation.
Asunto(s)
Plaquetas/citología , Megacariocitos/citología , Modelos Biológicos , Actinas/análisis , Plaquetas/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Línea Celular , Gránulos Citoplasmáticos/ultraestructura , Citometría de Flujo , Factor de Transcripción GATA1/genética , Factor de Transcripción GATA1/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Megacariocitos/metabolismo , Proteínas de Microfilamentos/genética , Proteínas de Microfilamentos/metabolismo , Subunidad p45 del Factor de Transcripción NF-E2/genética , Subunidad p45 del Factor de Transcripción NF-E2/metabolismo , Selectina-P/genética , Selectina-P/metabolismo , Recuento de Plaquetas , Glicoproteínas de Membrana Plaquetaria/genética , Glicoproteínas de Membrana Plaquetaria/metabolismo , Polimerizacion/efectos de los fármacos , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Acetato de Tetradecanoilforbol/farmacología , Trombina/farmacología , Trombopoyetina/farmacología , Trombospondinas/genética , Trombospondinas/metabolismo , TransactivadoresRESUMEN
The development of bone marrow fibrosis and thrombosis are main causes of morbidity in essential thrombocythemia (ET). Monocyte activation has been associated to the production of fibrosis-related cytokines and pro-thrombotic factors. The aim of this study was to identify new markers of monocyte activation in Phi-negative myeloproliferative neoplasms and to search for their relationship with clinical features. Forty-five patients comprising 30 ET, eight myelofibrosis and seven polycythemia vera were included. We evaluated the alpha subunit of IL-2 receptor (CD25) on monocytes, basal and LPS-induced IL-1beta release from mononuclear cells, and monocyte TGF-beta mRNA content. Patients who had thrombotic events displayed higher monocyte CD25 levels (6.2%) than those without symptoms (1.3%) and controls (2.6%), p=0.0006. JAK2V617F-positive patients had higher monocyte CD25 expression levels (4.7%), than JAK2V617F-negative (2.6%), p=0.0213. Patients with myeloproliferative neoplasms had similar monocyte CD25 expression than controls, both, in basal conditions and after cell adhesion. IL-1beta release and TGF-beta mRNA levels were normal. In conclusion, increased monocyte CD25 expression is associated with history of thrombosis and is also up-regulated in patients harboring JAK2V617F mutation. The finding of increased CD25 levels together with normal IL-1beta and TGF-beta production reveals a selective monocyte activation profile in myeloproliferative neoplasms.
Asunto(s)
Subunidad alfa del Receptor de Interleucina-2/metabolismo , Janus Quinasa 2/genética , Monocitos/metabolismo , Mutación/genética , Trastornos Mieloproliferativos/complicaciones , Trastornos Mieloproliferativos/enzimología , Trombosis/complicaciones , Adulto , Anciano , Sustitución de Aminoácidos/genética , Estudios de Casos y Controles , Femenino , Humanos , Interleucina-1beta/metabolismo , Masculino , Persona de Mediana Edad , Trastornos Mieloproliferativos/patología , Trombocitemia Esencial/complicaciones , Trombocitemia Esencial/genética , Trombocitemia Esencial/patología , Trombosis/enzimología , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismo , Adulto JovenAsunto(s)
Trombocitemia Esencial/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Sustitución de Aminoácidos , Antitrombina III/metabolismo , Niño , Femenino , Humanos , Hidroxiurea , Masculino , Persona de Mediana Edad , Inhibidores de Agregación Plaquetaria/uso terapéutico , Proteína C/metabolismo , Protrombina/genética , Quinazolinas/uso terapéutico , Valores de Referencia , Trombocitemia Esencial/complicaciones , Trombocitemia Esencial/tratamiento farmacológico , Trombofilia/complicacionesRESUMEN
Antiphospholipid syndrome is characterized by recurrent fetal loss, arterial and venous thromboses, thrombocytopenia and circulating antiphospholipid antibodies. Few patients have a rapidly progressive, fatal outcome. We report two young patients with systemic lupus erythematosus and antiphospholipid antibodies who died after a short course of disease. Although clinical and laboratory findings differed in both patients--small vessel thromboses and microangiopathic hemolytic anemia mimicking thrombotic thrombocytopenic purpura predominated in one of the patients while small and medium size vessel thromboses without hemolysis were present in the other case--autopsy revealed widespread visceral thromboses in both of them, features consistent with a diagnosis of catastrophic antiphospholipid syndrome. This syndrome has not been reported to occur in association with Pneumocistis carinii pneumonia as we describe in one of our patients.
Asunto(s)
Síndrome Antifosfolípido/complicaciones , Lupus Eritematoso Sistémico/complicaciones , Adulto , Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/patología , Endocarditis Bacteriana/complicaciones , Resultado Fatal , Femenino , Humanos , Lupus Eritematoso Sistémico/patología , Neumonía por Pneumocystis/diagnóstico , Trombosis/complicacionesRESUMEN
Antiphospholipid syndrome is characterized by recurrent fetal loss, arterial and venous thromboses, thrombocytopenia and circulating antiphospholipid antibodies. Few patients have a rapidly progressive, fatal outcome. We report two young patients with systemic lupus erythematosus and antiphospholipid antibodies who died after a short course of disease. Although clinical and laboratory findings differed in both patients--small vessel thromboses and microangiopathic hemolytic anemia mimicking thrombotic thrombocytopenic purpura predominated in one of the patients while small and medium size vessel thromboses without hemolysis were present in the other case--autopsy revealed widespread visceral thromboses in both of them, features consistent with a diagnosis of catastrophic antiphospholipid syndrome. This syndrome has not been reported to occur in association with Pneumocistis carinii pneumonia as we describe in one of our patients.
RESUMEN
Pulmonary arterial hypertension (PAH) and cor pulmonale were found in a patient with paroxysmal nocturnal hemoglobinuria (PNH). Autopsy revealed widespread thromboses in pulmonary microvasculature. Vascular thromboses attributed to hypercoagulability have been found in PNH in many organs, including the lungs. PAH has not been reported, however. This disease should then be considered a rare cause of PAH.